All Stories

  1. Development pathways for subcutaneous formulations of biologics versus biosimilar development

    Article • Expert Review of Precision Medicine and Drug Development, February 2019, Taylor & Francis

    George Bakalos

  2. Comparative immunogenicity assessment of biosimilars

    Article • Future Oncology, October 2018, Future Medicine

    George Bakalos

  3. Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients

    Article • Alimentary Pharmacology & Therapeutics, March 2018, Wiley

    George Bakalos

  4. Reply to ‘Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers’

    Article • ESMO Open, October 2017, BMJ

    George Bakalos

  5. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study

    Article • Annals of Gastroenterology, January 2017, Hellenic Society of Gastroenterology

    George Bakalos

  6. IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study

    Article • SpringerPlus, November 2016, Springer Science + Business Media

    George Bakalos

  7. Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, I...

    Article • Advances in Therapy, August 2016, Springer Science + Business Media

    George Bakalos

  8. Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial

    Article • Infectious Diseases and Therapy, May 2016, Springer Science + Business Media

    George Bakalos

  9. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort

    Article • PLoS ONE, March 2016, PLOS

    George Bakalos

  10. A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin

    Article • PLoS ONE, March 2016, PLOS

    George Bakalos

  11. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients

    Article • Liver International, November 2014, Wiley

    George Bakalos

  12. Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial

    Article • Hepatology International, July 2014, Springer Science + Business Media

    George Bakalos

  13. Assessing the relative effectiveness and tolerability of treatments in small cell lung cancer: A network meta-analysis

    Article • Cancer Epidemiology, October 2013, Elsevier

    George Bakalos

  14. A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis

    Article • Journal of Clinical Pharmacy and Therapeutics, August 2013, Wiley

    George Bakalos

  15. Variants of the MTHFR gene and susceptibility to acute lymphoblastic leukemia in children: A synthesis of genetic association studies

    Article • Cancer Epidemiology, April 2012, Elsevier

    Dimitrios Ziogas, George Bakalos

  16. Evidence of Association BetweenMethylenetetrahydrofolate ReductaseGene and Susceptibility to Breast Cancer: A Candidate-Gene Association Study in a South-Eastern European Population

    Article • DNA and Cell Biology, February 2012, Mary Ann Liebert Inc

    Dimitrios Ziogas, George Bakalos

  17. Advanced life support versus basic life support in the pre-hospital setting: A meta-analysis

    Article • Resuscitation, September 2011, Elsevier

    George Bakalos